Thrombocytosis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 359: | Line 359: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |Rare familial disease | | align="center" style="background:#F5F5F5;" + |Rare familial disease, middle age male and female | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Family history of thrombocytosis | * Family history of thrombocytosis | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Normal | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
Line 378: | Line 378: | ||
* [[Myelofibrosis|Megakaryocytic]] fragments | * [[Myelofibrosis|Megakaryocytic]] fragments | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | * Proliferation of [[Megakaryocyte|megakaryocytes]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |NA | ||
| align="center" style="background:#F5F5F5;" + |Genetic study | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mendelian inheritance | * Mendelian inheritance |
Revision as of 17:42, 29 August 2018
Thrombocytosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thrombocytosis differential diagnosis On the Web |
American Roentgen Ray Society Images of Thrombocytosis differential diagnosis |
Risk calculators and risk factors for Thrombocytosis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Thrombocytosis Differential Diagnosis
Differentiating the diseases that can cause thrombocytosis :
Category | Condition | Etiology | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | ||||||||||||||||||||||||
Lab Findings | Imaging | ||||||||||||||||||||||||||
Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | ||||||||||||||||
Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Plt | HB | WBC | ||||||||||||||||||||||
Autonomous thrombocytosis | Hematologic malignancies | Essential thrombocythemia[1] |
|
+ | - | - | - | + | Mean age >60 years old, female > male |
|
± | Flushing | + | Nl | + | - | ↑↑ | ↑ | ↑ |
|
Nl | Nl |
|
Bone marrow biopsy |
| ||
Polycythemia vera[2] |
|
+ | - | - | - | + | Mean age >60 years old |
|
- | Facial plethora | ± | Nl | + | - | ↑ | ↑↑ | ↑ |
|
|
↑ | ↑ | Bone marrow biopsy |
| ||||
Primary myelofibrosis[3] |
|
+ | - | - | - | + | Mean age >60 years old, male> female |
|
- | Pallor | + | Nl | + | + |
|
↑/↓ | ↓ | ↓ |
|
|
↑ | ↑ | Bone marrow biopsy |
| |||
Chronic myeloid leukemia[4] |
|
+ | - | - | - | + | Mean age >50 years old, male> female | History of exposure to: | + | + | Nl | + | - |
|
↑ | ↓ | ↑ |
|
|
↑ | ↑ |
|
Bone marrow biopsy |
| |||
Acute myeloid leukemia[5] |
|
+ | - | - | - | + | Median age of 63 years old |
|
+ | + | Nl | + | + |
|
↑/↓ | ↓ | ↑/↓ |
|
|
↑ | ↑ | NA | Bone marrow examination + clinical manifestation |
| |||
Myelodysplastic syndromes[6] |
|
+ | - | - | -/+ | + | Elderly | Exposure to | +/- | Petechiae, purpura, diffuse erythematous rash | + | Nl | + | + | ↑/↓ | ↓ | ↓ |
|
|
Nl | Nl | NA | Bone marrow examination + clinical manifestation |
| |||
Condition | Etiology | Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Inherited | Acquried | Demography | History | Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | Imaging | Gold standard | Associated findings | ||
Familial thrombocytosis[7][8] |
|
+ | - | - | + | - | Rare familial disease, middle age male and female |
|
- | Normal | - | Nl | - | - | - | ↑ | Nl | Nl |
|
|
Nl | Nl | NA | Genetic study |
| ||
Reactive thrombocytosis | Anemia/
blood loss |
|
+ |
|
↑ | ↓ |
| ||||||||||||||||||||
Infection | Chronic infections | + | + | ↑ | ↑ | ||||||||||||||||||||||
Tuberculosis | + | + | ↑ | ↑ | |||||||||||||||||||||||
Acute bacterial and viral infections | + | + | ↑ | ↑ | |||||||||||||||||||||||
Inflammation | Vasculitides | + | + | ↑ | ↑ | ||||||||||||||||||||||
Acute pancreatitis | + | + | ↑ | ↑ | |||||||||||||||||||||||
Malignancy | + | + | ↑ | ↑ | |||||||||||||||||||||||
Condition | Etiology | Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Inherited | Acquried | Demography | History | Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | Imaging | Gold standard | Associated findings | ||
Tissue damage | Thermal burns | ↑ | |||||||||||||||||||||||||
Trauma | ↑ | ||||||||||||||||||||||||||
Myocardial infarction | ↑ | ||||||||||||||||||||||||||
Medication | Myelosuppressive agents | ↑ | |||||||||||||||||||||||||
Vincristine | ↑ | ||||||||||||||||||||||||||
Epinephrine, glucocorticoids | ↑ | ||||||||||||||||||||||||||
Interleukin-1B | ↑ | ||||||||||||||||||||||||||
All-trans retinoic acid | ↑ | ||||||||||||||||||||||||||
Thrombopoietin | ↑ | ||||||||||||||||||||||||||
Other | Post-splenectomy or functional asplenia | + |
|
↑ |
|
||||||||||||||||||||||
Allergic reactions | ↑ | ||||||||||||||||||||||||||
Exercise | ↑ | ||||||||||||||||||||||||||
Pseudothrombocytosis | Mixed cryoglobulinemia | ||||||||||||||||||||||||||
Cytoplasmic fragments | |||||||||||||||||||||||||||
Category | Condition | Etiology | Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Inherited | Acquried | Demography | History | Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | Imaging | Gold standard | Associated findings |
References
- ↑ Brière, Jean B (2007). Orphanet Journal of Rare Diseases. 2 (1): 3. doi:10.1186/1750-1172-2-3. ISSN 1750-1172. Missing or empty
|title=
(help) - ↑ Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.
- ↑ Tefferi, Ayalew; Lasho, Terra L.; Jimma, Thitina; Finke, Christy M.; Gangat, Naseema; Vaidya, Rakhee; Begna, Kebede H.; Al-Kali, Aref; Ketterling, Rhett P.; Hanson, Curtis A.; Pardanani, Animesh (2012). "One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience". Mayo Clinic Proceedings. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. ISSN 0025-6196.
- ↑ Thompson, Philip A.; Kantarjian, Hagop M.; Cortes, Jorge E. (2015). "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015". Mayo Clinic Proceedings. 90 (10): 1440–1454. doi:10.1016/j.mayocp.2015.08.010. ISSN 0025-6196.
- ↑ Rose-Inman, Hayley; Kuehl, Damon (2014). "Acute Leukemia". Emergency Medicine Clinics of North America. 32 (3): 579–596. doi:10.1016/j.emc.2014.04.004. ISSN 0733-8627.
- ↑ Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.
- ↑ Ding, J. (2004). "Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin". Blood. 103 (11): 4198–4200. doi:10.1182/blood-2003-10-3471. ISSN 0006-4971.
- ↑ Wiestner, A.; Padosch, S. A.; Ghilardi, N.; Cesar, J. M.; Odriozola, J.; Shapiro, A.; Skoda, R. C. (2000). "Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia". British Journal of Haematology. 110 (1): 104–109. doi:10.1046/j.1365-2141.2000.02169.x. ISSN 0007-1048.